881 results on '"Jarolim, Petr"'
Search Results
2. FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF
3. Monitoring Temporal Changes in SARS-CoV-2 Spike Antibody Levels and Variant-Specific Risk for Infection, Dominican Republic, March 2021-August 2022
4. Neutrophil-lymphocyte ratio and clinical outcomes in 19,697 patients with atrial fibrillation: Analyses from ENGAGE AF- TIMI 48 trial
5. Longitudinal SARS-CoV-2 Nucleocapsid Antibody Kinetics, Seroreversion, and Implications for Seroepidemiologic Studies
6. Abstract 14745: Stem Cell Factor Associated With Critical Limb Ischemia in Patients With Peripheral Artery Disease
7. Calibrating from Within: Multipoint Internal Calibration of a Quantitative Mass Spectrometric Assay of Serum Methotrexate
8. SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection – A multistage national household survey and modelling study, Dominican Republic, June–October 2021
9. Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFrEF)
10. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
11. Convergence of SARS-CoV-2 Spike Antibody Levels to a Population Immune Setpoint
12. Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61
13. Abstract 14726: Serial Assessment of Cardiac Biomarkers and Risk of Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58
14. Abstract 11802: Hypocretin/Orexin Receptor-2 Influences Mortality Risk After Myocardial Infarction
15. Abstract 10465: Abnormal Post Exercise Skeletal Muscle Microvascular Response and Metabolism Correlate With Patient Reported Outcomes in Patients With Intermittent Claudication From Peripheral Artery Disease
16. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial
17. Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab
18. Using Regional Sero-Epidemiology SARS-CoV-2 Anti-S Antibodies in the Dominican Republic to Inform Targeted Public Health Response
19. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry
20. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells
21. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial
22. Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial
23. The Role of GDF-15 in Heart Failure Patients With Chronic Kidney Disease
24. Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61.
25. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure
26. Biomarkers in the IL-6 Pathway and Cardiovascular Outcomes in Patients With STEMI in LATITUDE-TIMI 60
27. Laboratory Formularies
28. Myocardial Injury and Cardiac Reserve in Patients With Heart Failure and Preserved Ejection Fraction
29. Causes of Troponin Elevation and Associated Mortality in Young Patients
30. 74-Year-old female with new monoclonal protein on serum immunofixation electrophoresis
31. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes
32. Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation
33. FGF-23 is a Biomarker of RV Dysfunction and Congestion in Patients with HFrEF
34. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
35. GROWTH DIFFERENTIATION FACTOR-15, CLINICAL OUTCOMES, AND THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHTS FROM THE DAPA-HF TRIAL
36. CA125 IN PATIENTS WITH HFREF AND THE EFFECT OF DAPAGLIFLOZIN: INSIGHTS FROM DAPA-HF
37. NT-PROBNP, BODY MASS INDEX, AND HEART FAILURE RISK IN CAMELLIA-TIMI 61
38. Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58
39. Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58
40. Abstract 13117: Incorporation of High-Sensitivity Troponin Along With the AHA/ACC Cholesterol Guidelines for Improved Risk Stratification and Targeted PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
41. Heart rate response to exercise in heart failure patients: The prognostic role of metabolic–chronotropic relation and heart rate recovery
42. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study
43. Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights From the PEGASUS-TIMI 54 Trial
44. Tracking immune correlates of protection for emerging SARS-CoV-2 variants
45. Neutrophil-Lymphocyte Ratio and Clinical Outcomes in 19,697 Patients with Atrial Fibrillation: Analyses from ENGAGE AF-TIMI 48 Trial
46. Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome
47. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial
48. Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure
49. Differential Clinical Profiles, Exercise Responses, and Outcomes Associated With Existing HFpEF Definitions
50. Implementation of an Emergency Department High-Sensitivity Troponin Chest Pain Pathway in the United States
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.